AgomAb Therapeutics NV (AGMB)

AgomAb Therapeutics NV Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-56.88	-46.27	-11.39	-8.14
Depreciation & Amortization	0.39	0.31	0.1	0.02
Stock-Based Compensation	4.43	1.07	2.16	2.21
Other Operating Activities	3.64	-0.66	-19.58	-14.47
Change in Accounts Payable	-1.79	-0.23	3.69	2.95
Change in Unearned Revenue	0.77	-0.4	-0.58	1.45
Change in Other Net Operating Assets	-1.57	-0.66	1.01	-2.99
Operating Cash Flow	-51.01	-46.83	-24.59	-18.97
Capital Expenditures	-0.36	-0.68	-	-
Cash Acquisitions	-3	-	-	-4.59
Investment in Securities	-	-	40	-40
Investing Cash Flow	-3.36	-0.68	40	-44.59
Long-Term Debt Issued	-	-	-	0.14
Long-Term Debt Repaid	-	-0.16	-0.1	-0.72
Net Debt Issued (Repaid)	-0.37	-0.16	-0.1	-0.58
Issuance of Common Stock	82.06	97.06	79.87	38.39
Other Financing Activities	-0.13	-0.13	-0.45	-0.17
Financing Cash Flow	81.56	96.76	79.32	37.63
Foreign Exchange Rate Adjustments	-0.2	-0.2	-	-
Miscellaneous Cash Flow Adjustments	0	0	-	-
Net Cash Flow	26.99	49.06	94.73	-25.92
Free Cash Flow	-51.37	-47.5	-24.59	-18.97
Free Cash Flow Per Share	-2054.80	-1900.12	-983.68	-758.68
Cash Interest Paid	0.01	0.01	0.02	0.04
Cash Income Tax Paid	0	0	0	0
Levered Free Cash Flow	-	-16.51	-49.9	-
Unlevered Free Cash Flow	-	-16.47	-49.88	-
Change in Working Capital	-2.59	-1.28	4.12	1.41

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q